Response Rate of Cervicofacial Lymphangioma to Sclerotherapy (Bleomycin Injection): Case-Series from Single Institution

Alonazi M, Alsinan T, Alonazi N, Sulaiman A, Alotaibi A and Almohaidly M

Prince Sultan Military Medical City, Riyadh City, Saudi Arabia

^*Correspondance to: Mohammad Alonazi 

 PDF  Full Text Case Series | Open Access

Abstract:

Background: Lymphangiomas, arising from developmental anomalies in lymphatic tissue, pose challenges in treatment due to their infiltrative nature. Sclerotherapy, particularly with bleomycin, has emerged as an alternative to surgery, showcasing promising results in prior studies. Objective: This retrospective study aimed to assess the response rates of cervicofacial lymphatic malformations to intralesional bleomycin therapy. Methods: A retrospective case series was conducted on pediatric patients (0-12 years) diagnosed with cervicofacial lymphangiomas who underwent intralesional bleomycin therapy at our institution between 2005 and 2012. Data including demographics, lesion characteristics, treatment details, complications, and response rates were collected and analyzed. Results: The study comprised seven patients (5 males, 2 females) with cervicofacial lymphangiomas, predominantly on the left side. Following intralesional bleomycin therapy, response rates were categorized as excellent (57.1%), good (28.6%), and poor (14.2%), with no major complications observed. Conclusion: Intralesional bleomycin emerges as a safe and effective therapeutic option for cervicofacial lymphangiomas. Despite variations in treatment response, its commendable safety profile and promising efficacy advocate for its consideration in managing these challenging malformations.

Keywords:

#

Cite the Article:

Alonazi M, Alsinan T, Alonazi N, Sulaiman A, Alotaibi A, Almohaidly M. Response Rate of Cervicofacial Lymphangioma to Sclerotherapy (Bleomycin Injection): Case-Series from Single Institution. Clin Case Rep Int. 2024; 8: 1692.